- Home
- CIGL vs TCRX Comparison
CIGL vs TCRX Comparison
Compare CIGL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGL
- TCRX
- Stock Information
- Founded
- CIGL 1997
- TCRX 2018
- Country
- CIGL Singapore
- TCRX United States
- Employees
- CIGL N/A
- TCRX N/A
- Industry
- CIGL Diversified Commercial Services
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CIGL Consumer Discretionary
- TCRX Health Care
- Exchange
- CIGL Nasdaq
- TCRX Nasdaq
- Market Cap
- CIGL 145.9M
- TCRX 90.5M
- IPO Year
- CIGL 2025
- TCRX 2021
- Fundamental
- Price
- CIGL $5.62
- TCRX $1.45
- Analyst Decision
- CIGL
- TCRX Strong Buy
- Analyst Count
- CIGL 0
- TCRX 6
- Target Price
- CIGL N/A
- TCRX $9.50
- AVG Volume (30 Days)
- CIGL 34.8K
- TCRX 774.8K
- Earning Date
- CIGL 01-01-0001
- TCRX 05-06-2025
- Dividend Yield
- CIGL N/A
- TCRX N/A
- EPS Growth
- CIGL N/A
- TCRX N/A
- EPS
- CIGL N/A
- TCRX N/A
- Revenue
- CIGL $10,490,668.00
- TCRX $4,421,000.00
- Revenue This Year
- CIGL N/A
- TCRX $68.86
- Revenue Next Year
- CIGL N/A
- TCRX $14.01
- P/E Ratio
- CIGL N/A
- TCRX N/A
- Revenue Growth
- CIGL N/A
- TCRX N/A
- 52 Week Low
- CIGL $3.63
- TCRX $1.02
- 52 Week High
- CIGL $7.27
- TCRX $9.29
- Technical
- Relative Strength Index (RSI)
- CIGL N/A
- TCRX 49.42
- Support Level
- CIGL N/A
- TCRX $1.33
- Resistance Level
- CIGL N/A
- TCRX $1.49
- Average True Range (ATR)
- CIGL 0.00
- TCRX 0.11
- MACD
- CIGL 0.00
- TCRX 0.02
- Stochastic Oscillator
- CIGL 0.00
- TCRX 69.12
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.